Last reviewed · How we verify
NCT05195320
Reinventing Yourself With Multiple Sclerosis (MS)
NA trial testing Reinvention with MS in Multiple Sclerosis in 48 participants. Status unknown.
30 September 2024
Quick facts
| Lead sponsor | Kessler Foundation |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 48 |
| Start date | 1 August 2022 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Reinvention with MS
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
Sponsor
Kessler Foundation
Who can join
18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Given the knowledge that detriments in QOL, well-being, and participation are common in MS and attributable in a large part to individual, person-specific factors (e.g., self-efficacy), efforts to develop interventions aimed at addressing these factors is well needed and likely to have a significant impact. The proposed investigation will consist of two phases involving participant recruitment and data collection. Phase 1 will consist of a focus group aimed at identifying the unique needs of individuals with MS, and findings will be used to adapt the Reinventing Yourself after Spinal Cord Injury (SCI) intervention to Reinventing Yourself with MS. Phase 2 will consist of a randomized controlled trial (RCT) in which the feasibility and efficacy of the intervention in a new population can be examined.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05195320
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other Kessler Foundation trials
Trials by the same sponsor.
- NCT07168941 — Evaluation and Refinement of KF-STRIDE Into the Interview! · NA · not yet recruiting
- NCT07159100 — tDCS for Cancer-Related Fatigue and Weakness · EARLY_PHASE1 · not yet recruiting
- NCT06886152 — Spinal Stimulation and Gait Training to Improve Mobility in TBI · NA · not yet recruiting
- NCT07073313 — Using Muscle Functional MRI to Study Spatial Muscle Activation Patterns in People With SCI · not yet recruiting
- NCT06923293 — Improving Walking After a Lower Limb Injury Using a Custom Motorized Orthosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05195320 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kessler Foundation
- Last refreshed: 14 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05195320.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing